|
|
|
| home > epc > spring 2002 > maintaining validation control over edc systems during a clinical study |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
A lot has been written about the benefits of implementing electronic data capture (EDC) in the context of clinical studies. Topics commonly covered include the regulations, guidance and standards against which EDC solutions are created and implemented, the methods for maintaining data security, and those for measuring and delivering a return on investment, not to mention the general ways in which EDC affects and improves the processes of data gathering and what the future holds.
Despite the discussion about EDC there has been limited use of the technology throughout pharmaceutical companies' development pipelines. Whilst 50 per cent of companies may claim to have used EDC, this has commonly only been in pilot phase. This level of maturity is reflected in the industry estimates that EDC is still only used in between 5 per cent and 10 per cent of studies commenced on an annual basis (1).
Companies are grappling with the practical aspects of EDC implementation in a constantly changing environment. This situation presents particularly interesting challenges for the clinical research organisation (CRO) community. CROs find themselves either trying to implement a 'standard EDC solution' or deliver flexibility to their clients. Both approaches have their limiting factors. As the market matures, perhaps the latter approach best enables CROs to take advantage of the EDC technology which proves itself to satisfy the needs of their market segment.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
C21 Bioventures
22-24 May 2012, Napa, CA
C21 BioVentures™ (C21), annually held in Napa Valley California at the Meritage Resort May 22-24, 2012, is an intimate venue designed for small –privately held enterprises to showcase innovation and to network with potential partners for funding sources. In today’s economic climate, life science companies have found they must make changes or continued existence will be difficult.
More info >> |
|
 |
News and Press Releases |
 |
APTAR PHARMA CELEBRATES ASTHMA DAY WITH A TWISTER™ OF INNOVATION
World leader in the development and manufacturing of nasal and pulmonary drug delivery devices including inhalers for asthma, Aptar Pharma launches Twister™, a new versatile affordable capsule-based Dry Powder Inhaler (DPI) specifically targeting fast growing markets.
More info >> |
|
|
